Eugenio J Maul1, Alan Kastner2, Jimena Schmidt2, Jaime A Tapia2, Cristobal Morales2, Eugenio A Maul3. 1. Department of Ophthalmology, School of Medicine, Pontificia Universidad Católica de Chile, Ave. Apoquindo 3990 Suite 708, PC:7550112, Santiago, Chile. emauld@gmail.com. 2. Department of Ophthalmology, School of Medicine, Pontificia Universidad Católica de Chile, Ave. Apoquindo 3990 Suite 708, PC:7550112, Santiago, Chile. 3. Department of Ophthalmology, School of Medicine, Universidad de los Andes, Santiago, Chile.
Abstract
PURPOSE: To assess the cumulative risk of progression in glaucomatous eyes in the severe stage of disease. METHODS: This was a retrospective observational study. Patients that had severe damage in at least one eye, as defined by three criteria including a mean deviation of ≤ - 20 dB, were included. Glaucoma progression was defined as a loss of ≥ 2 dB in mean deviation confirmed in three consecutive visual field tests, or a persistent loss of two or more lines of vision-not attributable to non-glaucomatous causes-in three consecutive follow-up examinations. Kaplan-Meier survival analysis was used to assess the cumulative incidence of progression of the first eye to reach endpoint in cases where both eyes were eligible. RESULTS: A total of 143 eyes from 119 patients, were studied over a mean period of 4.9 ± 2.9 years. Baseline mean deviation was - 25.3 ± 3.6 dB. Twenty-three eyes of 22 patients reached the progression endpoint: 14 eyes by visual field criteria and 9 by visual acuity criteria. The cumulative 5-year risk of progression estimated by Kaplan-Meier analysis was 14.6% (95% confidence interval: 6.1-22.2%). CONCLUSIONS: In severe glaucoma patients, we found a cumulative incidence of progression of 2.9% per year during the first 5 years of follow-up. Similar incidences have been reported in other studies of glaucoma at different stages of severity.
PURPOSE: To assess the cumulative risk of progression in glaucomatous eyes in the severe stage of disease. METHODS: This was a retrospective observational study. Patients that had severe damage in at least one eye, as defined by three criteria including a mean deviation of ≤ - 20 dB, were included. Glaucoma progression was defined as a loss of ≥ 2 dB in mean deviation confirmed in three consecutive visual field tests, or a persistent loss of two or more lines of vision-not attributable to non-glaucomatous causes-in three consecutive follow-up examinations. Kaplan-Meier survival analysis was used to assess the cumulative incidence of progression of the first eye to reach endpoint in cases where both eyes were eligible. RESULTS: A total of 143 eyes from 119 patients, were studied over a mean period of 4.9 ± 2.9 years. Baseline mean deviation was - 25.3 ± 3.6 dB. Twenty-three eyes of 22 patients reached the progression endpoint: 14 eyes by visual field criteria and 9 by visual acuity criteria. The cumulative 5-year risk of progression estimated by Kaplan-Meier analysis was 14.6% (95% confidence interval: 6.1-22.2%). CONCLUSIONS: In severe glaucomapatients, we found a cumulative incidence of progression of 2.9% per year during the first 5 years of follow-up. Similar incidences have been reported in other studies of glaucoma at different stages of severity.
Entities:
Keywords:
Glaucoma; Humphrey; Progression; Severe; Visual field damage
Authors: Richard P Mills; Donald L Budenz; Paul P Lee; Robert J Noecker; John G Walt; Lisa R Siegartel; Stacy J Evans; John J Doyle Journal: Am J Ophthalmol Date: 2006-01 Impact factor: 5.258
Authors: Kouros Nouri-Mahdavi; Douglas Hoffman; Anne L Coleman; Gang Liu; Gang Li; Douglas Gaasterland; Joseph Caprioli Journal: Ophthalmology Date: 2004-09 Impact factor: 12.079
Authors: Seth R Flaxman; Rupert R A Bourne; Serge Resnikoff; Peter Ackland; Tasanee Braithwaite; Maria V Cicinelli; Aditi Das; Jost B Jonas; Jill Keeffe; John H Kempen; Janet Leasher; Hans Limburg; Kovin Naidoo; Konrad Pesudovs; Alex Silvester; Gretchen A Stevens; Nina Tahhan; Tien Y Wong; Hugh R Taylor Journal: Lancet Glob Health Date: 2017-10-11 Impact factor: 26.763
Authors: Anthony J King; Gordon Fernie; Augusto Azuara-Blanco; Jennifer M Burr; Ted Garway-Heath; John M Sparrow; Luke Vale; Jemma Hudson; Graeme MacLennan; Alison McDonald; Keith Barton; John Norrie Journal: Br J Ophthalmol Date: 2017-10-26 Impact factor: 4.638